Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
Amgen announced the FDA approved Amgen's sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia, a rare, serious autoimmune disease characterized by low platelet counts. October 18, 2019